V. Wette

发表

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

R. Greil, M. Gnant, R. Exner, 2019, The Lancet. Oncology.

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

R. Greil, W. Eiermann, M. Gnant, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.

R. Greil, M. Gnant, H. Geinitz, 2020, European journal of cancer.

Improving survival rates for patients with colorectal cancer

V. Wette, G. Jatzko, P. Lisborg, 1992, The British journal of surgery.

Recurrent nerve palsy after thyroid operations--principal nerve identification and a literature review.

V. Wette, G. Jatzko, P. Lisborg, 1994, Surgery.

Sphincter preservation — A fascinating challenge in rectal carcinoma surgery

M. Klimpfinger, M. Horn, V. Wette, 1994, Acta chirurgica Austriaca.

Extraperitonealization of the anastomosis and sacral drain in restorative surgery for rectal carcinoma: A safety mechanism in the absence of a covering stoma

V. Wette, G. Jatzko, P. Lisborg, 1996, Surgery Today.

Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial

R. Greil, M. Gnant, P. Dubsky, 2018 .

The potential risk of neoadjuvant chemotherapy in breast cancer patients—results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)

R. Greil, M. Gnant, H. Samonigg, 2008, Breast Cancer Research and Treatment.

The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.

R. Greil, M. Gnant, Z. Bago-Horvath, 2020, European journal of cancer.

Simultaneous resection of colorectal carcinoma and synchronous liver metastases in a district hospital

H. Denk, M. Klimpfinger, V. Wette, 1991, International Journal of Colorectal Disease.

[Surgical emergency interventions in acute diseases of the large intestine].

M. Horn, V. Wette, G. Jatzko, 1992, Zentralblatt fur Chirurgie.

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response

M. Gnant, Z. Bago-Horvath, P. Dubsky, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

M. Gnant, H. Samonigg, R. Jakesz, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxi fen Versus Tamoxi fen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal

M. Gnant, H. Samonigg, R. Jakesz, 2003 .

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.

M. Gnant, H. Samonigg, R. Jakesz, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term Prognosis for Colon Cancer Related to Consistent Radical Surgery: Multivariate Analysis of Clinical, Surgical, and Pathologic Variables

H. Denk, H. Stettner, M. Klimpfinger, 2000, World Journal of Surgery.

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34

R. Greil, M. Gnant, Z. Bago-Horvath, 2021, British Journal of Cancer.

Abstract GS6-04: The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2- breast cancer patients from ABCSG 34

R. Greil, M. Gnant, P. Regitnig, 2018 .

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)

E. Winer, D. Lake, M. Gnant, 2022, Journal of Clinical Oncology.

Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer

H. Denk, O. Tsybrovskyy, K. Zatloukal, 2004, Virchows Archiv.

Abstract S2-02: The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial

R. Greil, J. Bergh, F. Kainberger, 2016 .

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

R. Greil, J. Bergh, F. Kainberger, 2015, The Lancet.

Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.

R. Greil, J. Bergh, M. Gnant, 2018 .

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.

R. Greil, M. Gnant, R. Jakesz, 2021, The New England journal of medicine.

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).

R. Greil, M. Gnant, Z. Bago-Horvath, 2020, European journal of cancer.

Abstract P6-10-01: Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)

R. Greil, Z. Bago-Horvath, P. Dubsky, 2017 .

Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.

R. Greil, J. Bergh, F. Kainberger, 2022, NEJM evidence.

[Surgical therapy and results in stomach cancer at an Austrian regional hospital].

M. Klimpfinger, V. Wette, G. Jatzko, 1989, Zeitschrift fur Gastroenterologie.

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).

E. Winer, D. Lake, M. Gnant, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.